Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Birzeit Pharmaceutical CoXPAE:BPC -1.36%87 EV-to-EBIT is 9.90 as of Aug. 10, 2026, which is 3% below its 10-year median of 10.19. GuruFocus rates XPAE:BPC with a GF Score™ of 87/100 and a GF Value™ of $4.59 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, Birzeit Pharmaceutical Co ranks better than 70.72% on this metric.
Birzeit Pharmaceutical Co (XPAE:BPC) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Birzeit Pharmaceutical Co's Enterprise Value for the quarter that ended in Mar. 2026 was $151.52 Mil.
Birzeit Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co EV-to-EBIT Related Terms
Birzeit Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAE:BPC vs ZTS, UTHR, VTRS: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Birzeit Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Birzeit Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Birzeit Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Birzeit Pharmaceutical Co's EV-to-EBIT falls into.
Birzeit Pharmaceutical Co's current Enterprise Value is $137.56 Mil.
Birzeit Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $13.89 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Birzeit Pharmaceutical Co (XPAE:BPC) has a EV-to-EBIT of 9.90 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Birzeit Pharmaceutical Co and its competitors. This is near median its historical median of 10.19. Over the past decade, Birzeit Pharmaceutical Co's EV-to-EBIT has ranged from 7.00 to 44.39. According to the industry distribution chart, Birzeit Pharmaceutical Co ranks #200 out of 683 companies in the Drug Manufacturers industry, placing it in the top 29.3%.
Is Birzeit Pharmaceutical Co's EV-to-EBIT too high?
Birzeit Pharmaceutical Co's current EV-to-EBIT of 9.90 is near median its 10-year median of 10.19. Over the past 10 years, this metric has ranged from a low of 7.00 to a high of 44.39. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Birzeit Pharmaceutical Co's value of 9.90 is 36.8% below this industry median. Based on the distribution chart, Birzeit Pharmaceutical Co ranks #200 out of 683 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Birzeit Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Birzeit Pharmaceutical Co's EV-to-EBIT compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Birzeit Pharmaceutical Co ranks #200 out of 683 companies for EV-to-EBIT. This puts Birzeit Pharmaceutical Co in the upper half of its industry. The industry median EV-to-EBIT is 15.66. Birzeit Pharmaceutical Co's value of 9.90 is 36.8% below this benchmark. Historically, Birzeit Pharmaceutical Co's own EV-to-EBIT has ranged from 7.00 to 44.39 over the past decade. While the company's 10-year median is 10.19 vs. the industry median of 15.66, Birzeit Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Birzeit Pharmaceutical Co's current EV-to-EBIT of 9.90 is 36.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Birzeit Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Birzeit Pharmaceutical Co's current EV-to-EBIT is 9.90, which is near median its own 10-year median of 10.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Birzeit Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co (XPAE:BPC) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.59, compared to a current price of $3.62 — trading 21.1% below its estimated fair value. The current EV-to-EBIT is 9.90, which is near median its 10-year median of 10.19 and 36.8% below the Drug Manufacturers industry median of 15.66. Birzeit Pharmaceutical Co's overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Birzeit Pharmaceutical Co (XPAE:BPC), the current EV-to-EBIT is 9.90 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Birzeit Pharmaceutical Co (XPAE:BPC) Overvalued in 2026?
Based on GuruFocus' analysis, Birzeit Pharmaceutical Co stock appears to be undervalued.
The current stock price of $3.62 is trading 21.1% below its estimated GF Value™ of $4.59.
GuruFocus considers Birzeit Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for XPAE:BPC:
EV-to-EBIT: 9.90 (near median its 10-year median of 10.19)
GF Value™: $4.59 vs. price of $3.62 (21.1% below fair value)
Industry Position: 36.8% below the Drug Manufacturers median (#200 of 683)
No single metric tells the full story. See the XPAE:BPC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Birzeit Pharmaceutical Co operates as a pharmaceutical manufacturer in Palestine, producing a range of approximately 270 products across various production lines at four locations. Its portfolio comprises brands spanning multiple therapeutic areas. In addition to manufacturing, the company supplies its products to the local market through pharmacies and medical professionals.
87GF Score
Get the complete analysis for XPAE:BPC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAE:BPC has been successfully added to your 
